Physician profile
Lisa Looper
NPI 1265947386
$2,421.36
in general payments reported to CMS, 2019-2025
27 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,013 · 2022: $236 · 2023: $94.00 · 2024: $33.29 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.24 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $414.75 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $332.09 | 2021-2025 | |
| Pfizer INC. | $265.12 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.60 | 2021 | |
| Abbott Laboratories | $136.38 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $131.08 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $123.94 | 2021-2025 | Airsupra |
| Astellas Pharma US INC | $112.24 | 2021-2023 | |
| Glaxosmithkline, LLC. | $106.56 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.38 | 2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.17 | 2025 | Caplyta |
| Amgen INC. | $66.57 | 2021-2025 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $64.14 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $41.50 | 2025 | Symbravo |
| Nevro Corp. | $35.72 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $34.59 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $33.58 | 2021 | |
| Exact Sciences Corporation | $32.92 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $30.36 | 2021 | |
| Esperion Therapeutics, INC. | $22.79 | 2021 | |
| Nestle Healthcare Nutrition INC. | $21.48 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.90 | 2024 | Quviviq |
| Amarin Pharma, INC. | $18.48 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.97 | 2021 | |
| Eisai INC. | $15.53 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.83 | 2021 | |
| Phathom Pharmaceuticals, INC. | $10.69 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Looper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.